Abstracts tagged "PRO and SLE"

Abstract Number: 1420 • 2016 ACR/ARHP Annual Meeting
Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Meenakshi Jolly¹, Nisarg Gandhi², Winston Sequeira² and Joel Block², ¹Rush, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Disease Specific Patient reported outcome measures capture unique domains relevant to patients with a specific disease. LupusPRO is targeted towards measuring health (HRQOL) and…
Abstract Number: 1421 • 2016 ACR/ARHP Annual Meeting
Responsiveness of Lupus Impact Tracker Among Chinese Patients with Lupus
Chi Chiu Mok¹, Meenakshi Jolly² and Joel Block³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rush, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT), a 10 item, patient reported outcome tool for patients with systemic lupus erythematosus (SLE) has undergone psychometric validation and responsiveness…
Abstract Number: 787 • 2015 ACR/ARHP Annual Meeting
Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Meenakshi Jolly¹, Nisarg Gandhi², Alana Nevares³ and Winston Sequeira², ¹Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Internal Medicine, Cook County Hospital, Chicago, IL
Background/Purpose: Disease Specific Patient reported outcome measure tools capture unique domains relevant to patients with a specific disease. LupusPRO is targeted towards measuring health (HRQOL)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].